Xenitra has secured a three-year procurement agreement worth at least A$12 million with Kangsheng, a leading Chinese pharmaceutical distributor, marking its OTC pharmaceuticals division's shift from setup to commercial execution.
- Three-year A$12 million procurement deal with Kangsheng
- Agreement marks commercial launch of OTC pharmaceuticals division
- Access to China’s large healthcare market via established distributor
- Deal complements Xenitra’s nutritionals and OPAL token sales pillars
- Initial orders expected after operational onboarding this quarter
Milestone Procurement Deal Accelerates OTC Pharmaceuticals Launch
Xenitra Limited (ASX:XEN) has turned a significant corner in its healthcare strategy by signing a three-year pharmaceutical procurement agreement with Kangsheng Hong Kong International Trading Limited, one of China’s top omnichannel pharmaceutical distributors. The deal commits Kangsheng to purchase a minimum of A$12 million worth of over-the-counter (OTC) medicines and health products through Xenitra’s recently acquired Hong Kong subsidiary, Fukang, over the next three years.
This agreement transitions Xenitra’s OTC pharmaceuticals pillar from regulatory groundwork and supply chain build-out into tangible commercial execution, validating its multi-pronged growth approach alongside its nutritionals and OPAL tokenised sales platforms. Kangsheng’s established distribution network spans e-commerce and retail pharmacies with annual revenues exceeding RMB 900 million (approximately A$190 million), providing Xenitra immediate access to one of the world’s largest and fastest-growing healthcare consumption markets.
Strategic Distribution Partnership Unlocks China Market
Rather than a one-off transaction, the Kangsheng deal integrates seamlessly into Xenitra’s broader China distribution ecosystem, which combines e-commerce, livestream commerce, and distributor infrastructure to scale international and domestic FMCG brands. The partnership offers a ready-made channel to bring global OTC pharmaceutical brands into China at scale, bypassing the lengthy process of building comparable reach organically.
Non-Executive Chairman Dr Anthony Noble highlighted the deal as a key execution milestone, underscoring that it completes the company’s three-pillar growth strategy. He noted the complementary nature of the OTC pharmaceuticals division with the nutritionals business, anchored by a $30 million per annum partnership with Rockcheck, and the rapidly growing OPAL real-world-asset tokenised sales platform.
Commercial Terms and Market Implications
The agreement spans from July 2026 to July 2029 and requires Kangsheng to place quarterly and annual orders totaling at least A$12 million. Products covered include prescription and OTC medicines sourced globally, with a focus on Australian and European markets. Payment terms are staged, with deposits and balances tied to order confirmation, dispatch, and receipt verification.
Kangsheng’s selection of Fukang as a core supply-chain partner offers external validation of Xenitra’s sourcing capabilities and distribution model. The deal also signals concurrent progress across the company’s three growth pillars, each now underpinned by live commercial activity, providing multiple avenues for shareholder value creation.
Next Steps and Operational Onboarding
Initial commercial orders are expected to commence following the completion of operational onboarding within this quarter, marking the official start of revenue generation from this division. The partnership also opens the door for deeper strategic collaboration to expand Xenitra’s FMCG and healthcare footprint across the Asia-Pacific region.
Investors will be watching how quickly Xenitra can leverage Kangsheng’s extensive network to convert this procurement agreement into sustained sales momentum, particularly as it complements the company’s ongoing growth in the OPAL tokenised sales ecosystem, which recently surpassed $1.1 million in sales with over 400 distribution partners in just seven weeks.
Bottom Line?
Xenitra’s Kangsheng deal transforms its OTC pharmaceuticals from concept to commercial reality, setting the stage for meaningful revenue growth in China’s lucrative healthcare market.
Questions in the middle?
- How rapidly will initial orders translate into sustained sales volume under the Kangsheng partnership?
- Can Xenitra expand this strategic relationship to include more product lines or broader Asia-Pacific markets?
- What impact will concurrent growth in nutritionals and OPAL tokenised sales have on overall company profitability?